Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2

COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive...

Descripción completa

Detalles Bibliográficos
Autores principales: Parashar, Nidarshana Chaturvedi, Poddar, Jit, Chakrabarti, Sasanka, Parashar, Gaurav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417262/
https://www.ncbi.nlm.nih.gov/pubmed/32791240
http://dx.doi.org/10.1016/j.meegid.2020.104497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417262/
https://www.ncbi.nlm.nih.gov/pubmed/32791240
http://dx.doi.org/10.1016/j.meegid.2020.104497

Ejemplares similares